A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-11-15
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 31); relationship: not assessed
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 260); relationship: not assessed
severe
assessed
Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-07 (study day 284); relationship: not assessed
moderate
assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-06-11 (study day 562); relationship: not assessed
Data queries
No data queries.